COVID-19 vaccine trials: Duty of care and standard of prevention considerations.
作者信息
Singh Jerome Amir
机构信息
CAPRISA, University of KwaZulu-Natal, Durban, South Africa; Department of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada; Howard College School of Law, University of KwaZulu-Natal, King George V Ave, Durban 4001, South Africa.
出版信息
Vaccine. 2020 Nov 10;38(48):7578-7580. doi: 10.1016/j.vaccine.2020.10.012. Epub 2020 Oct 9.
Abstract
摘要
相似文献
1
COVID-19 vaccine trials: Duty of care and standard of prevention considerations.2019冠状病毒病疫苗试验：注意义务与预防标准考量
Vaccine. 2020 Nov 10;38(48):7578-7580. doi: 10.1016/j.vaccine.2020.10.012. Epub 2020 Oct 9.
2
Keeping track of the SARS-CoV-2 vaccine pipeline. 跟踪 SARS-CoV-2 疫苗研发管线。
Nat Rev Immunol. 2020 Nov;20(11):650. doi: 10.1038/s41577-020-00455-1.
3
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.布莱顿协作组织（ Brighton Collaboration ）用于收集灭活病毒疫苗的获益-风险评估关键信息的标准化模板。
Vaccine. 2020 Sep 3;38(39):6184-6189. doi: 10.1016/j.vaccine.2020.07.028. Epub 2020 Jul 31.
4
Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.探索新冠疫苗加速反应中的不确定性和风险：来自制药行业的观点。
Vaccine. 2020 Nov 10;38(48):7588-7595. doi: 10.1016/j.vaccine.2020.10.034. Epub 2020 Oct 13.
5
Advances in skin science enable the development of a COVID-19 vaccine.皮肤科学的进展推动了新冠疫苗的研发。
J Am Acad Dermatol. 2020 Oct;83(4):1226-1227. doi: 10.1016/j.jaad.2020.05.126. Epub 2020 May 30.
6
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗：全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
7
Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials.在英国的“人体挑战”试验中，数十人将被故意感染新冠病毒。
Nature. 2020 Oct;586(7831):651-652. doi: 10.1038/d41586-020-02821-4.
8
The Race to Develop a COVID-19 Vaccine.新冠疫苗研发竞赛。
Am J Nurs. 2020 Oct;120(10):14-15. doi: 10.1097/01.NAJ.0000718556.85319.00.
9
COVID-19 herd immunity: where are we?COVID-19 群体免疫：我们在哪里？
Nat Rev Immunol. 2020 Oct;20(10):583-584. doi: 10.1038/s41577-020-00451-5.
10
Reporting COVID-19: A Conversation with Jon Cohen of Science.报道新冠疫情：与《科学》杂志的乔恩·科恩对话
Am J Trop Med Hyg. 2020 Oct;103(4):1744-1747. doi: 10.4269/ajtmh.20-1034.
引用本文的文献
1
Factors Associated with Intention to Receive COVID-19 Vaccine Among HIV Positive Patients Attending ART Clinic in Southwest Ethiopia.埃塞俄比亚西南部接受抗逆转录病毒治疗门诊的HIV阳性患者中与接种新冠疫苗意愿相关的因素
Patient Prefer Adherence. 2021 Dec 9;15:2731-2738. doi: 10.2147/PPA.S342801. eCollection 2021.
2
COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology.新型冠状病毒肺炎与癌症：从基本机制到利用纳米技术进行疫苗开发
Int Immunopharmacol. 2021 Jan;90:107247. doi: 10.1016/j.intimp.2020.107247. Epub 2020 Dec 2.
3
The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.赋予 COVID-19 候选疫苗紧急使用授权：对 COVID-19 疫苗试验的影响。
Lancet Infect Dis. 2021 Apr;21(4):e103-e109. doi: 10.1016/S1473-3099(20)30923-3. Epub 2020 Dec 8.
本文引用的文献
1
Extraordinary diseases require extraordinary solutions.特殊的疾病需要特殊的解决方案。
Vaccine. 2020 May 19;38(24):3987-3988. doi: 10.1016/j.vaccine.2020.04.039. Epub 2020 Apr 20.
2
The COVID-19 vaccine development landscape.2019冠状病毒病疫苗的研发情况。
Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5.
3
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.人类挑战研究加速冠状病毒疫苗许可。
J Infect Dis. 2020 May 11;221(11):1752-1756. doi: 10.1093/infdis/jiaa152.
4
Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.在确定 HIV 预防试验的预防包标准时的伦理考虑：检查 PrEP。
Dev World Bioeth. 2013 Aug;13(2):87-94. doi: 10.1111/dewb.12032. Epub 2013 May 31.
Zotero 插件